About the study
CHINOOK is a Phase 4 study of benralizumab, an approved biologic for severe eosinophilic asthma, compared with placebo. It looks at whether treatment changes the structure of the airways (airway remodeling) and lung function over a 48-week treatment period, using airway biopsies and detailed CT imaging.
Who took part
The study enrolled people who:
- Were 18 to 70 years old
- Had severe asthma with high eosinophil counts that was not controlled on high-dose inhaled steroid plus a long-acting bronchodilator
Status at Veritas
This study is active but no longer enrolling new participants. People already enrolled continue their study visits.
Learn more
The full study record, including all eligibility criteria and outcome measures, is on ClinicalTrials.gov (NCT03953300).